Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum

J Neurochem. 2005 May;93(3):762-5. doi: 10.1111/j.1471-4159.2005.03134.x.


Precise regulation of dopaminergic activity is of obvious importance for the physiology and pathology of basal ganglia. We report here that nanomolar concentrations of the astrocyte-derived neuroinhibitory metabolite kynurenic acid (KYNA) potently reduce the extracellular levels of striatal dopamine in unanesthetized rats in vivo. This effect, which is initiated by the KYNA-induced blockade of alpha7 nicotinic acetylcholine receptors, highlights the functional relevance of glia-neuron interactions in the striatum and indicates that even modest increases in the brain levels of endogenous KYNA are capable of interfering with dopaminergic neurotransmission.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Corpus Striatum / drug effects*
  • Corpus Striatum / metabolism
  • Dopamine / metabolism*
  • Dose-Response Relationship, Drug
  • Extracellular Fluid / drug effects*
  • Extracellular Fluid / metabolism
  • Kynurenic Acid / administration & dosage*
  • Male
  • Nanotechnology / methods*
  • Rats
  • Rats, Sprague-Dawley


  • Kynurenic Acid
  • Dopamine